Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 2/2012

01.04.2012 | Case Report

Efficient palliative involved-field radiotherapy on highly progressive diffuse large B-cell primary gastric lymphoma with liver cirrhosis

verfasst von: Junji Kohisa, Kenya Kamimura, Akito Iwanaga, Kazuhiko Shioji, Hirokazu Kawai, Takeshi Suda, Kenji Suzuki, Junko Sakurada, Makoto Naito, Yutaka Aoyagi

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

We report the case of a 73-year-old woman having diffuse large B-cell primary gastric lymphoma with a cirrhotic liver caused by hepatitis C virus infection. She visited our hospital with symptoms of nausea and vomiting, which appeared to be caused by stenosis due to the tumor. Metastatic tumors were seen in the gastric and jugular lymph nodes. The clinical stage was IVB with a high risk of poor prognosis according to the international index. Because of poor hepatic reserve function, standard chemotherapy could not be administered. To maintain her quality of life, palliative involved-field radiotherapy was performed. The symptoms and tumor markers significantly improved, and computed tomography and endoscopy indicated the disappearance of the primary gastric tumor. Two months after radiotherapy and her return home, she died of pneumonia. Autopsy showed neither lymphoma cells nor stenosis of gastric lesion. The significant anti-tumor effect on primary tumor in our case suggests that the involved-field radiotherapy, although palliative, can be a therapeutic option for primary gastric lymphoma patients with various complications.
Literatur
1.
Zurück zum Zitat Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L. Gastrointestinal involvement in non-Hodgkin’s lymphoma. Cancer. 1980;46:215–22.PubMedCrossRef Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L. Gastrointestinal involvement in non-Hodgkin’s lymphoma. Cancer. 1980;46:215–22.PubMedCrossRef
2.
Zurück zum Zitat Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol. 2007;136:521–38.PubMedCrossRef Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol. 2007;136:521–38.PubMedCrossRef
3.
Zurück zum Zitat Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma—results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19:3874–83.PubMed Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma—results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19:3874–83.PubMed
4.
Zurück zum Zitat Fischbach W. Long-term follow-up of gastric lymphoma after stomach conserving treatment. Best Pract Res Clin Gastroenterol. 2010;24:71–7.PubMedCrossRef Fischbach W. Long-term follow-up of gastric lymphoma after stomach conserving treatment. Best Pract Res Clin Gastroenterol. 2010;24:71–7.PubMedCrossRef
5.
Zurück zum Zitat Psyrri A, Papageorgiou S, Economopoulos T. Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol. 2008;19:1992–9.PubMedCrossRef Psyrri A, Papageorgiou S, Economopoulos T. Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol. 2008;19:1992–9.PubMedCrossRef
6.
Zurück zum Zitat Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17:697–707.PubMedCrossRef Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17:697–707.PubMedCrossRef
7.
Zurück zum Zitat Kim WS, Park YH, Lee SH, Ryoo BY, Yang SH, Lee SS, et al. Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. Med Oncol. 2008;25:447–50.PubMedCrossRef Kim WS, Park YH, Lee SH, Ryoo BY, Yang SH, Lee SS, et al. Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. Med Oncol. 2008;25:447–50.PubMedCrossRef
8.
Zurück zum Zitat Fischbach W, Schramm S, Goebeler E. Outcome and quality of life favour a conservative treatment of patients with primary gastric lymphoma. Z Gastroenterol. 2011;49:430–5.PubMedCrossRef Fischbach W, Schramm S, Goebeler E. Outcome and quality of life favour a conservative treatment of patients with primary gastric lymphoma. Z Gastroenterol. 2011;49:430–5.PubMedCrossRef
9.
Zurück zum Zitat Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–6.PubMedCrossRef Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–6.PubMedCrossRef
10.
Zurück zum Zitat Aleman BM, Haas RL, van der Maazen RW. Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24:27–34.PubMedCrossRef Aleman BM, Haas RL, van der Maazen RW. Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24:27–34.PubMedCrossRef
11.
Zurück zum Zitat Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology. 2012;55:634–41.PubMedCrossRef Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology. 2012;55:634–41.PubMedCrossRef
12.
Zurück zum Zitat Kocher M, Muller RP, Ross D, Hoederath A, Sack H. Radiotherapy for treatment of localized gastrointestinal non-Hodgkin’s lymphoma. Radiother Oncol. 1997;42:37–41.PubMedCrossRef Kocher M, Muller RP, Ross D, Hoederath A, Sack H. Radiotherapy for treatment of localized gastrointestinal non-Hodgkin’s lymphoma. Radiother Oncol. 1997;42:37–41.PubMedCrossRef
13.
Zurück zum Zitat Tanaka Y, Takao T, Watanabe H, Kido T, Ogawa N, Iwase K, et al. Early stage gastric lymphoma: is operation essential? World J Surg. 1994;18:896–9.PubMedCrossRef Tanaka Y, Takao T, Watanabe H, Kido T, Ogawa N, Iwase K, et al. Early stage gastric lymphoma: is operation essential? World J Surg. 1994;18:896–9.PubMedCrossRef
14.
Zurück zum Zitat Lybeert ML, De Neve W, Vrints LW, Coen V, Coebergh JW. Primary gastric non-Hodgkin’s lymphoma stage IE and IIE. Eur J Cancer. 1996;32A:2306–11.PubMedCrossRef Lybeert ML, De Neve W, Vrints LW, Coen V, Coebergh JW. Primary gastric non-Hodgkin’s lymphoma stage IE and IIE. Eur J Cancer. 1996;32A:2306–11.PubMedCrossRef
15.
Zurück zum Zitat Aviles A, Fernandezb R, Perez F, Nambo MJ, Neri N, Talavera A, et al. Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma. 2004;45:1385–9.PubMedCrossRef Aviles A, Fernandezb R, Perez F, Nambo MJ, Neri N, Talavera A, et al. Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma. 2004;45:1385–9.PubMedCrossRef
16.
Zurück zum Zitat de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6:451–8.PubMedCrossRef de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6:451–8.PubMedCrossRef
17.
Zurück zum Zitat Nieters A, Kallinowski B, Brennan P, Ott M, Maynadie M, Benavente Y, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case–control study EPILYMPH. Gastroenterology. 2006;131:1879–86.PubMedCrossRef Nieters A, Kallinowski B, Brennan P, Ott M, Maynadie M, Benavente Y, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case–control study EPILYMPH. Gastroenterology. 2006;131:1879–86.PubMedCrossRef
18.
Zurück zum Zitat Schollkopf C, Smedby KE, Hjalgrim H, Rostgaard K, Panum I, Vinner L, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer. 2008;122:1885–90.PubMedCrossRef Schollkopf C, Smedby KE, Hjalgrim H, Rostgaard K, Panum I, Vinner L, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer. 2008;122:1885–90.PubMedCrossRef
19.
Zurück zum Zitat Ito M, Kusunoki H, Mochida K, Yamaguchi K, Mizuochi T. HCV infection and B-cell lymphomagenesis. Adv Hematol. 2011 (In press). Ito M, Kusunoki H, Mochida K, Yamaguchi K, Mizuochi T. HCV infection and B-cell lymphomagenesis. Adv Hematol. 2011 (In press).
20.
Zurück zum Zitat Arcaini L, Merli M, Passamonti F, Bruno R, Brusamolino E, Sacchi P, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin’s lymphomas. Am J Hematol. 2010;85:46–50.PubMed Arcaini L, Merli M, Passamonti F, Bruno R, Brusamolino E, Sacchi P, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin’s lymphomas. Am J Hematol. 2010;85:46–50.PubMed
21.
Zurück zum Zitat Nosotti L, D’Andrea M, Pitidis A, Pimpinelli F, Dessanti ML, Pisani F, et al. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin’s lymphoma patients treated with immunochemotherapy. Scand J Infect Dis. 2012;44:70–3.PubMedCrossRef Nosotti L, D’Andrea M, Pitidis A, Pimpinelli F, Dessanti ML, Pisani F, et al. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin’s lymphoma patients treated with immunochemotherapy. Scand J Infect Dis. 2012;44:70–3.PubMedCrossRef
22.
Zurück zum Zitat Nakai S, Masaki T, Shintani T, Deguchi A, Kimura Y, Himoto T, et al. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma. Oncol Rep. 2005;13:1065–8.PubMed Nakai S, Masaki T, Shintani T, Deguchi A, Kimura Y, Himoto T, et al. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma. Oncol Rep. 2005;13:1065–8.PubMed
23.
Zurück zum Zitat Foxton MR, Knight L, Knisely AS, Mufti GJ, O’Grady J, Muiesan P, et al. Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pretreated with rituximab. Liver Transpl. 2005;11:839–42.PubMedCrossRef Foxton MR, Knight L, Knisely AS, Mufti GJ, O’Grady J, Muiesan P, et al. Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pretreated with rituximab. Liver Transpl. 2005;11:839–42.PubMedCrossRef
24.
Zurück zum Zitat Nooka A, Shenoy PJ, Sinha R, Lonial S, Flowers CR. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2011;11:379–84.PubMedCrossRef Nooka A, Shenoy PJ, Sinha R, Lonial S, Flowers CR. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2011;11:379–84.PubMedCrossRef
25.
Zurück zum Zitat Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis. 2012;44:49–54.PubMedCrossRef Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis. 2012;44:49–54.PubMedCrossRef
26.
Zurück zum Zitat Pellicelli AM, Zoli V. Role of ribavirin in hepatitis flare in HCV-infected patients with B cell non Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig Liver Dis. 2011;43:501–2.PubMedCrossRef Pellicelli AM, Zoli V. Role of ribavirin in hepatitis flare in HCV-infected patients with B cell non Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig Liver Dis. 2011;43:501–2.PubMedCrossRef
27.
Zurück zum Zitat Marignani M, Mangone M, Cox MC, Angeletti S, Veggia B, Ferrari A, et al. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig Liver Dis. 2011;43:139–42.PubMedCrossRef Marignani M, Mangone M, Cox MC, Angeletti S, Veggia B, Ferrari A, et al. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig Liver Dis. 2011;43:139–42.PubMedCrossRef
28.
Zurück zum Zitat Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116:3815–24.PubMedCrossRef Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116:3815–24.PubMedCrossRef
29.
Zurück zum Zitat Gobbi PG, Corbella F, Valentino F, Bergonzi M, Sangalli C, Perfetti V, et al. Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy. Ann Oncol. 2009;20:465–8.PubMedCrossRef Gobbi PG, Corbella F, Valentino F, Bergonzi M, Sangalli C, Perfetti V, et al. Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy. Ann Oncol. 2009;20:465–8.PubMedCrossRef
30.
Zurück zum Zitat Isobe K, Uno T, Kawakami H, Ueno N, Kawata T, Ito H. A case of gastric lymphoma with marked interfractional gastric movement during radiotherapy. Int J Clin Oncol. 2006;11:159–61.PubMedCrossRef Isobe K, Uno T, Kawakami H, Ueno N, Kawata T, Ito H. A case of gastric lymphoma with marked interfractional gastric movement during radiotherapy. Int J Clin Oncol. 2006;11:159–61.PubMedCrossRef
31.
Zurück zum Zitat Della Biancia C, Hunt M, Furhang E, Wu E, Yahalom J. Radiotherapy treatment planning techniques for lymphoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;62:745–51.PubMedCrossRef Della Biancia C, Hunt M, Furhang E, Wu E, Yahalom J. Radiotherapy treatment planning techniques for lymphoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;62:745–51.PubMedCrossRef
32.
Zurück zum Zitat Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;15:1646–54.CrossRef Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;15:1646–54.CrossRef
33.
Zurück zum Zitat Michaels AJ, Nelson DR. New therapies in the management of hepatitis C virus. Curr Opin Gastroenterol. 2010;26:196–201.PubMedCrossRef Michaels AJ, Nelson DR. New therapies in the management of hepatitis C virus. Curr Opin Gastroenterol. 2010;26:196–201.PubMedCrossRef
Metadaten
Titel
Efficient palliative involved-field radiotherapy on highly progressive diffuse large B-cell primary gastric lymphoma with liver cirrhosis
verfasst von
Junji Kohisa
Kenya Kamimura
Akito Iwanaga
Kazuhiko Shioji
Hirokazu Kawai
Takeshi Suda
Kenji Suzuki
Junko Sakurada
Makoto Naito
Yutaka Aoyagi
Publikationsdatum
01.04.2012
Verlag
Springer Japan
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 2/2012
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-012-0292-7

Weitere Artikel der Ausgabe 2/2012

Clinical Journal of Gastroenterology 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.